MedMatrix Rx
Daily 340B Morning Briefing for Executives
Recent developments surrounding the 340B program involve significant legal and legislative challenges. Drugmakers, including AbbVie, Bristol Myers Squibb, and Boehringer Ingelheim, have filed motions to intervene in a lawsuit aimed at blocking HRSA’s 340B rebate pilot program, which is set to replace upfront discounts with post-sale rebates starting in 2027. In response to these changes, a bipartisan bill has been introduced to delay the pilot by two years, pushing its implementation from 2027 to 2028. Meanwhile, health systems are bracing for substantial financial impacts from CMS’s proposed 340B payment cut, with estimated losses ranging from $7 million to $109 million annually. As HRSA’s rebate pilot faces mounting scrutiny, the future for covered entities remains uncertain, with potential repercussions for their financial viability and access to affordable medications.
EXECUTIVE SUMMARY
01
Drugmakers seek to intervene in 340B rebate lawsuit.
AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, and PhRMA filed motions to defend HRSA’s 340B Rebate Model Pilot Program in court.
AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, and PhRMA filed motions to defend HRSA’s 340B Rebate Model Pilot Program in court.
Source: Becker’s Hospital Review
02
New bill aims to delay 340B rebate pilot by two years.
Bipartisan legislation introduced to pause HRSA’s 340B rebate model pilot, requiring upfront discounts from 2027 to 2028.
Bipartisan legislation introduced to pause HRSA’s 340B rebate model pilot, requiring upfront discounts from 2027 to 2028.
Source: Becker’s Hospital Review
03
CMS’s proposed 340B payment cut could cost health systems millions.
Health systems estimate losses from CMS’s proposed 340B payment cut, with impacts ranging from $7 million to $109 million annually.
Health systems estimate losses from CMS’s proposed 340B payment cut, with impacts ranging from $7 million to $109 million annually.
Source: Becker’s Hospital Review
04
HRSA approves 10 drugmakers for 340B rebate pilot.
HRSA approved 10 manufacturers for a revised 340B rebate pilot program, replacing upfront discounts with post-sale rebates starting in 2027.
HRSA approved 10 manufacturers for a revised 340B rebate pilot program, replacing upfront discounts with post-sale rebates starting in 2027.
Source: Becker’s Hospital Review
05
Hospitals file lawsuit to block 340B rebate pilot.
American Hospital Association and others filed a lawsuit against HRSA’s 340B rebate pilot, citing financial viability concerns.
American Hospital Association and others filed a lawsuit against HRSA’s 340B rebate pilot, citing financial viability concerns.
Source: Healthcare Dive
06
CMS opens portal for 340B data submissions ahead of 2027 deadline.
CMS launched a Medicare Part D Claims Data 340B Repository for voluntary submissions, mandatory starting January 2027.
CMS launched a Medicare Part D Claims Data 340B Repository for voluntary submissions, mandatory starting January 2027.
Source: Becker’s Hospital Review
07
HRSA’s 340B rebate pilot faces legal and legislative challenges.
HRSA’s 340B rebate pilot is under legal scrutiny and legislative challenge, with lawsuits and a bill proposing a delay.
HRSA’s 340B rebate pilot is under legal scrutiny and legislative challenge, with lawsuits and a bill proposing a delay.
Source: Healthcare Dive
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The ongoing legal and legislative battles surrounding the 340B rebate pilot pose a threat to covered entities, particularly hospitals that rely on the program to provide discounted medications to vulnerable populations. The proposed shift from upfront discounts to post-sale rebates could disrupt cash flow and budgeting for these entities, leading to increased operational challenges. If the pilot is implemented as planned, health systems may face heightened financial strain, exacerbating existing vulnerabilities and potentially limiting their ability to serve low-income patients. The bipartisan effort to delay the pilot reflects a growing recognition of these risks and the need for a stable and predictable reimbursement environment to ensure that covered entities can continue to fulfill their mission of providing essential healthcare services.
Emerging risks.
- Hospitals face financial strain from potential administrative costs of the 340B rebate pilot.
- Legal battles could delay the implementation of the 340B rebate model, affecting planning and budgeting.
- Proposed CMS payment cuts could reduce hospital revenue from 340B drug sales.
- The shift to rebates may increase cash flow challenges for hospitals relying on upfront discounts.
- Ongoing litigation may create uncertainty in the 340B program’s future, impacting hospital operations.
Emerging opportunities.
- Hospitals can use the legislative delay to advocate for reforms that support their financial interests.
- Engagement in the legislative process provides a chance to shape future 340B program policies.
- Hospitals may explore alternative financial strategies to mitigate potential revenue loss from CMS cuts.
- The CMS data repository provides an opportunity for hospitals to improve data management and compliance.
- Stakeholders can collaborate to propose solutions that balance drug pricing and hospital financial health.
Key actions for providers.
- Hospitals should monitor the progress of the 340B rebate pilot lawsuit and legislative developments closely.
- Engage with lawmakers to support or oppose the 340B Rebate Model Delay Act as it relates to organizational goals.
- Prepare for potential changes in 340B payment structures by assessing financial impacts and adjusting strategies.
- Participate in CMS’s voluntary data submission to ensure readiness for the mandatory 2027 deadline.
- Evaluate the implications of HRSA’s rebate pilot approval on current 340B drug purchasing practices.
TOP STORIES
Drugmakers seek intervention in 340B rebate lawsuit.
Healthcare Dive · October 19, 2026
- Drugmakers filed motions to intervene in a lawsuit challenging HRSA’s 340B Rebate Model Pilot Program.
- The lawsuit, filed by hospitals, seeks to block the pilot’s implementation.
New bill proposes delay of 340B rebate pilot.
Becker’s Hospital Review · October 13, 2026
- Bipartisan bill introduced to pause HRSA’s 340B rebate pilot for two years.
- The bill requires upfront 340B discounts during the delay period.
CMS’s proposed 340B payment cut impacts health systems.
Becker’s Hospital Review · October 12, 2026
- Health systems estimate losses from CMS’s proposed 340B payment cut range from $7 million to $109 million annually.
- CMS’s 2027 outpatient payment rule would cut drug payments by $4.55 billion in the first year.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
HRSA approves 10 drugmakers for 340B rebate pilot.
Becker’s Hospital Review · October 2, 2026
- HRSA approved 10 manufacturers for a revised 340B rebate pilot starting in 2027.
- The pilot replaces upfront discounts with post-sale rebates for a limited set of drugs.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| D. Me. | AMERICAN HOSPITAL ASSOCIATION v. KENNEDY — Motion to Intervene by AbbVie Inc., pharmacyclics LLC, bristol-myers squibb company, boehringer ingelheim pharmaceuticals, inc. Responses due by 11/4/2026. Case filed October 9, 2026. [source] | October 14, 2026 |
| M.D. Fla. | Florida Health Sciences Center, Inc. v. Eli Lilly and Company — Response to Motion re motion to Dismiss Plaintiff’s Complaint and As-Applied Challenge to the Constitutionality of Section 501.201 to 501.213, Fla. Stat. Case filed July 2, 2026. [source] | October 14, 2026 |
| S.D.N.Y. | Mount Sinai Hospital v. CVS Health Corporation — Protective ORDER.regarding procedures to be followed that shall govern the handling of confidential material. (.). Case filed May 18, 2026. [source] | October 13, 2026 |
| D.N.H. | Mary Hitchcock Memorial Hospital v. Eli Lilly and Company — Surreply to Reply to 5 motion for Preliminary Injunction Def’s Surreply in Opposition to Plt’s Motion for Preliminary Injunction. Case filed July 27, 2026. [source] | October 6, 2026 |
| 8th Cir. | Astrazeneca Pharmaceuticals, LP v. Marty Jackley — Reply to response to petition for initial hearing en banc. Case filed August 11, 2026. [source] | September 25, 2026 |
| 8th Cir. | Pharm. Res. & Mfr. of America v. Marty Jackley — Motion to file a reply to response,. Case filed August 25, 2026. [source] | September 25, 2026 |
| N.D. Ill. | Novartis Pharmaceuticals Corporation v. Raoul, in his official capacity as Attorney General for the State of Illinois — Order signed by the Honorable Edmond E. Chang. For the reasons stated in the Order, the motion for expedited discovery 34 is denied. Case filed August 7, 2026. [source] | September 24, 2026 |
| E.D. Mo. | AbbVie Inc. v. Hanaway — Memorandum and order: Accordingly, the Court grants Intervenors’ motion to intervene. see order for details. Case filed July 22, 2024. [source] | September 24, 2026 |
WHAT TO WATCH NEXT
- Monitor the outcome of drugmakers’ motion to intervene in the 340B rebate lawsuit. [source]
- Track the legislative progress of the 340B Rebate Model Delay Act. [source]
- Watch for CMS’s final decision on the proposed 340B payment cut. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.